| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8624030 | Endocrinología y Nutrición | 2016 | 8 Pages |
Abstract
Empagliflozin combined with other oral treatments decreased HbA1c, body weight, and SBP/DBP as compared to placebo, with a good safety and tolerability profile.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Clinical Biochemistry
Authors
Irene Romera, Francisco Javier Ampudia-Blasco, Antonio Pérez, Bernat Ariño, Egon Pfarr, Sanja Giljanovic Kis, Ebrahim Naderali,